Armistice Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$19.2M |
| 2 |
Incyte
INCY
|
+$18.5M |
| 3 |
ASRT
Assertio
ASRT
|
+$17.4M |
| 4 |
Dick's Sporting Goods
DKS
|
+$15.9M |
| 5 |
Campbell Soup
CPB
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hain Celestial
HAIN
|
+$27.8M |
| 2 |
SGI
Somnigroup International
SGI
|
+$20.7M |
| 3 |
United Parks & Resorts
PRKS
|
+$13.7M |
| 4 |
GCI
Gannett Co., Inc
GCI
|
+$13.4M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.77% |
| 2 | Consumer Discretionary | 18.98% |
| 3 | Consumer Staples | 9.7% |
| 4 | Industrials | 3.8% |
| 5 | Technology | 0.08% |
Similar funds
Armistice Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Armistice Capital held 87 positions worth $849M, up 8.2% from $785M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Armistice Capital deployed $67.4M of net new capital in Q3 2017, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was United Therapeutics: 150,000 shares worth $17.6M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $11.5M trimmed.
- Armistice Capital's largest Q3 2017 buy was United Therapeutics: 150,000 shares worth $17.6M.
- Armistice Capital added most to Assertio in Q3 2017, an estimated $17.4M increase.
- Armistice Capital's biggest Q3 2017 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $11.5M.
- Armistice Capital fully exited Hain Celestial in Q3 2017, selling an estimated $27.8M.
- Armistice Capital's ten largest holdings make up 45% of its $849M portfolio in Q3 2017.
- Armistice Capital opened 28 new positions and closed 22 in Q3 2017.
- Armistice Capital's portfolio value rose 8.2% quarter-over-quarter to $849M.
Based on Armistice Capital's 13F filing for Q3 2017, filed 14 Nov 2017.